Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 3/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10043824 | 0.85 | MAPT (0.42) | RAF1FGFR1SRC | |
| SCHEMBL10043948 | 0.83 | MAPK14 (0.42) | MAPK14MAPKAPK2MAPK13MAPK12MAPK11 | |
| SCHEMBL10043932 | 0.82 | MAPK14 (0.43) | MAPK14MAPKAPK2MAPK13MAPK12MAPK11 | |
| SCHEMBL501911 | 0.82 | SYK (0.46) | MAPK14MAPKAPK2MAPK13MAPK12MAPK11 | |
| SCHEMBL10043941 | 0.81 | ALDH1A1 (0.47) | MAPK14LCKKITKDR | |
| SCHEMBL502525 | 0.80 | MAPK14 (0.53) | MAPK14MAPKAPK2MAPK13MAPK12MAPK11 | |
| SCHEMBL10043931 | 0.80 | MAPK14 (0.47) | MAPK14MAPKAPK2MAPK13MAPK12MAPK11 | |
| SCHEMBL10043944 | 0.80 | SRC (0.41) | MAPK14MAPKAPK2MAPK13MAPK12MAPK11 | |
| SCHEMBL10043935 | 0.80 | RAB9A (0.47) | MAPK14MAPKAPK2MAPK13MAPK12MAPK11 | |
| SCHEMBL10043942 | 0.80 | PCTP (0.44) | MAPK14MAPKAPK2MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2010-04-01 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | MAPK14 117/4885MAPKAPK2 26/4885MAPK13 106/4885 |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | MAPK14 117/4885MAPKAPK2 26/4885MAPK13 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.